John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Biglari Holdings Class B
BH
$1.21B
| $495K | ﹤0.01% |
3,425
-3,066
| -47% | -$411K |
|
2002
Hawaiian Electric Industries
HE
$1.96B
| $494K | ﹤0.01% |
11,666
+206
| +2% | +$8.58K |
|
|
GLDG
2003
GoldMining Inc
GLDG
$253M
| $493K | ﹤0.01% |
+290,238
| New | +$484K |
|
2004
Holley
HLLY
$350M
| $493K | ﹤0.01% |
35,438
+13,385
| +61% | +$172K |
|
2005
Lipocine
LPCN
$17.7M
| $493K | ﹤0.01% |
21,181
+15,146
| +251% | +$317K |
|
|
CCRN
2006
DELISTED
Cross Country Healthcare
CCRN
| $491K | ﹤0.01% |
+22,641
| New | +$491K |
|
|
SCPL
2007
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
| $491K | ﹤0.01% |
38,000
-138,191
| -78% | -$1.75M |
|
2008
Merchants Bancorp
MBIN
$2.46B
| $489K | ﹤0.01% |
17,849
+2,393
| +15% | +$71.2K |
|
2009
Rackspace Technology
RXT
$867M
| $488K | ﹤0.01% |
+43,700
| New | +$516K |
|
2010
Valmont Industries
VMI
$9.13B
| $487K | ﹤0.01% |
+2,040
| New | +$464K |
|
2011
Mustang Bio
MBIO
$4.18M
| $486K | ﹤0.01% |
642
-321
| -33% | -$264K |
|
|
NOA
2012
North American Construction
NOA
$359M
| $486K | ﹤0.01% |
+33,647
| New | +$503K |
|
2013
Core Laboratories
CLB
$553M
| $485K | ﹤0.01% |
15,329
-119,950
| -89% | -$3.36M |
|
2014
TransAlta
TAC
$3.87B
| $485K | ﹤0.01% |
46,792
-845,286
| -95% | -$8.72M |
|
|
IGMS
2015
DELISTED
IGM Biosciences
IGMS
| $483K | ﹤0.01% |
18,057
-55,825
| -76% | -$1.04M |
|
|
TRVG
2016
trivago
TRVG
$389M
| $483K | ﹤0.01% |
40,956
+19,248
| +89% | +$217K |
|
|
NOTV
2017
DELISTED
Inotiv
NOTV
| $481K | ﹤0.01% |
+18,379
| New | +$516K |
|
|
CBIO
2018
Crescent Biopharma
CBIO
$631M
| $480K | ﹤0.01% |
4,208
-1,895
| -31% | -$222K |
|
2019
inTEST
INTT
$146M
| $480K | ﹤0.01% |
44,688
-59,280
| -57% | -$649K |
|
2020
VSE Corp
VSEC
$6.11B
| $480K | ﹤0.01% |
+10,405
| New | +$519K |
|
|
TIG
2021
DELISTED
Trean Insurance Group, Inc. Common Stock
TIG
| $480K | ﹤0.01% |
102,373
+66,424
| +185% | +$448K |
|
|
MMX
2022
DELISTED
Maverix Metals Inc. Common Shares
MMX
| $480K | ﹤0.01% |
99,931
+59,131
| +145% | +$273K |
|
2023
Kinsale Capital Group
KNSL
$8.84B
| $479K | ﹤0.01% |
+2,100
| New | +$438K |
|
2024
Puma Biotechnology
PBYI
$481M
| $479K | ﹤0.01% |
+166,451
| New | +$431K |
|
2025
VistaGen Therapeutics
VTGN
$11M
| $479K | ﹤0.01% |
12,887
-2,837
| -18% | -$124K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.